Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study

Wenfeng Chen; Wei Li; Yongchang Zhang; Huijie Fan; Qitao Yu; Feiwu Ran; Caicun Zhou

doi:10.1200/jco-26-00434

Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study

Долгосрочная эффективность и безопасность талетректиниба у пациентов с ROS1-положительным немелкоклеточным раком легкого: результаты исследования фазы II TRUST-I

Wenfeng Chen, Wei Li, Yongchang Zhang, Huijie Fan, Qitao Yu, Feiwu Ran, Caicun Zhou

2026-04-21

SCID: 54.1/t4g6jpjq Discuss with AI

ROS1-positive non-small cell lung cancerTRUST-I studylong-term efficacy and safetyphase IItaletrectinib

Abstract (AI)

+ NSCLC.

Key Findings

Taletrectinib was evaluated for long-term efficacy and safety in patients with ROS1-positive non–small cell lung cancer in the Phase II TRUST-I study.

Research Object

Taletrectinib treatment in patients with ROS1-positive non–small cell lung cancer

Research Subject

Long-term efficacy and safety outcomes of taletrectinib in ROS1+ NSCLC patients

Publication Details

DOI

10.1200/jco-26-00434

Publication Date

2026-04-21

Journal

Publisher

ISSN

Cited by

Open access PDF

https://doi.org/10.1200/jco-26-00434

Access Type

Author Information

Authors

Wenfeng Chen

Wei Li

Yongchang Zhang

Huijie Fan

Qitao Yu

Feiwu Ran

Caicun Zhou

Download PDF

Make a presentation

References available in scid.ai2

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer2024 Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST2025

Long-Term Efficacy and Safety of Taletrectinib in Patients With <i>ROS1</i> + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study